# Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients

Study · id `cardio:ct-nct07749014` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07749014](<https://clinicaltrials.gov/study/NCT07749014>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07749014

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 480 participants.

## Technical summary

Registry record NCT07749014. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2027-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 480 participants (planned count; ClinicalTrials.gov record NCT07749014, source copy `cardio:ctgov-nct07749014-2026-08-06`, retrieved 2026-10-26)
- Planned start: 2026-09-01 (anticipated) (ClinicalTrials.gov record NCT07749014, source copy `cardio:ctgov-nct07749014-2026-08-06`, retrieved 2026-10-26)
- Primary completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT07749014, source copy `cardio:ctgov-nct07749014-2026-08-06`, retrieved 2026-10-26)
- Completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT07749014, source copy `cardio:ctgov-nct07749014-2026-08-06`, retrieved 2026-10-26)
- Countries: Pakistan (ClinicalTrials.gov record NCT07749014, source copy `cardio:ctgov-nct07749014-2026-08-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07749014-2026-08-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
- Acronym: TEMPO-STEMI
- Condition: ST-elevation Myocardial Infarction (STEMI)
- Condition: Acute Myocardial Infarction (AMI)
- Condition: Coronary Artery Disease
- Intervention (Drug): empagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Rehman Medical Institute - RMI
- Lead sponsor class: OTHER
- Collaborator: Michigan State University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as a collaborator: Michigan State University (`cardio:org-michigan-state-university`)

## Provenance

Content hash: 6852ff9ce7cb27256364ccea2e8c0ae9cc354332edb12ca27645c0e17db2feab
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
